glp-1 and gip dual agonist 🔴Comparison of GLP-1R Mono-Agonist vs. GIPR/GLP-1R Therapy⤵️ #2025Review 1️⃣ RA are well-studied, but the mechanisms of receptor (GIPR) agonists remain less understood. 2️⃣ GLP-1R monotherapy (e.g., semaglutide) is Comparison between GLP-1 RA and

New molecules and indications for GLP-1 medicines

Not Suitable For: The treatment is not suitable for: Pregnant or Breastfeeding Individuals: Due to potential risks to the foetus or breastfeeding infant

And by educating patients on both the benefits and risks, we can help them become more alert and attuned to their GI symptoms even before they start this medication. Advertisement Advertisement A new study shows that an AI-enabled bundled system of sensors and coaching reduced A1C with fewer medications TRANSITION-T2D RCT results for patients with T2D receiving MDI Large retrospective analysis may prompt prospective studies Robust signal from observational study raises prospect of a long-sought medical therapy Post hoc analysis of SURPASS-CVOT trial has implications for future cardiovascular outcome trials Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies Emerging evidence suggests a patient-specific approach Looking at the real-world impact and the future pipeline of targeted therapies

Jun 16 2022;12(6)doi:10.3390/jpm12060980

The observed positive outcomes underscore the need for more comprehensive and rigorous research to explore the potential role of FMT in ameliorating gouty arthritis and its associated metabolic abnormalities